Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
About this trial
Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome
Eligibility criteria
Qualifiers
Adult (≥18 years)
Monomicrobial EF-BSI
Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy
Written informed consent
Disqualifiers
Short term (within 3 days from BSI) mortality
Other concomitant infection
Trial design
Treatments tested in this trial
- Not listed
Trial groups
510 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov